Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from DaVita

How Berkshire Hathaway Performed During Buffett's Final Quarter

Buffett’s final quarter saw a 25% drop in net income, but his final portfolio moves—including increased positions in Chubb and Chevron—have proven prescient.

MarketBeat

Berkshire’s New CEO Just Offloaded DaVita Stocks: Should You Sell Yours Too?

For the first time since 1965, Berkshire Hathaway has made a major trade under the direction of someone other than former CEO Warren Buffett. The conglomerate recently sold roughly 1.65 million shares...

GOBankingRates

DaVita Stock: Is Wall Street Bullish or Bearish?

Are Wall Street analysts bullish or bearish on DaVita’s stock after its fourth-quarter earnings?

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Hedge Funds Are Shorting This Classic Warren Buffett Stock. Should You Sell Shares Now?

Hedge funds are betting against DaVita, but low valuations and steady cash flow suggest this Buffett stock may be bruised, not broken.

Barchart

Here's What to Expect From DaVita's Next Earnings Report

DaVita is set to announce its fourth-quarter results soon, with analysts forecasting a double-digit increase in the company’s bottom-line figure.

Barchart

Behind Berkshire’s Curtain: Is Greg Abel Preparing to Cut Davita Loose?

Davita hit its 23rd new 52-week low on Tuesday. Its stock is now within a few dollars of trading in double digits. That’s not a good thing, given that its share price was nearly $180 a year ago.

Barchart

Is DaVita Stock Underperforming the Dow?

As DaVita has underperformed relative to the Dow over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

The Biggest Cybersecurity Threats to Watch Out For In 2026

This year, more than eight ransomware attacks occurred, targeting major companies such as Ingram, Microsoft, Volvo, and DaVita. In 2026, with the aid of AI and AI Agents, these attacks will likely see a spike like never before.

inkl

DaVita Stock: Analyst Estimates & Ratings

DaVita has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Barchart

Buffett's Berkshire Hathaway Sells 401K DaVita Shares Two Days Before Q3 Earnings Decline

Warren Buffett's Berkshire Hathaway sold over 401,000 shares of healthcare firm DaVita days before its stock price fell following lower Q3 earnings.

International Business Times UK

Is DaVita Stock Underperforming the Nasdaq?

As DaVita has considerably underperformed the Nasdaq recently, analysts remain cautious about the stock’s prospects.

Barchart

What's Going With Dialysis Firm DaVita Stock On Friday?

The U.S. health department's website reported that a ransomware attack between March and April against dialysis provider DaVita Inc. (NYSE:DVA) exposed the personal data of 2.7 million people.

Benzinga

Huge healthcare breach sees nearly a million patients hit following DaVita ransomware attack - make sure you're safe

Healthcare giant DaVita hit by Interlock attack, and warns patients to remain vigilant.

TechRadar

Over 900,000 hit in massive healthcare data breach — names, addresses and Social Security numbers exposed online

DaVita fell victim to a cyberattack back in March of this year during which time hackers gained unauthorized access to its servers.

Tom’s Guide

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Warren Buffett's Berkshire Hathaway Offloads $230 Million In DaVita Stock Ahead Of Q2 Earnings

Warren Buffett’s Berkshire Hathaway Inc. (NYSE:BRK) (NYSE:BRK) has sold off a significant portion of its holdings in DaVita Inc. (NYSE:DVA), a leading dialysis service provider, just before the latter’s Q2 earnings report.

GOBankingRates

7 Stocks Warren Buffet Has Sold So Far in 2025

If Buffett is unloading some stocks, it pays to take a closer look at their fundamentals. Here's a quick look at the stocks that he's been selling in 2025.

Barchart

DaVita’s Quarterly Earnings Preview: What You Need to Know

DaVita is expected to unveil its second-quarter results in the upcoming month, and analysts expect a single-digit rise in its profitability.

Barchart

Is DaVita Stock Underperforming the S&P 500?

DaVita’s performance over the past year has fallen short of the broader S&P 500 Index, prompting a neutral outlook from analysts regarding its future prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

DaVita CEO Javier Rodriguez: The Trump administration is 'very aggressive in trying to change the trajectory of health care'

Also: All the news and watercooler chat from Fortune.

International Business Times UK

Warren Buffett Sells $168M in Davita Shares One Day Before Dialysis Provider Hit by Lawsuit

Berkshire Hathaway chair Warren Buffett sold over a million shares of DaVita worth £126.23 million on 8th May, a day before the dialysis service provider was sued by an employee benefits plan.

Barchart

DaVita’s Q1 2025 Earnings: What to Expect

DaVita is expected to unveil its first-quarter results in the upcoming month, and analysts expect a significant double-digit drop in earnings.

TechRadar

Top kidney dialysis firm hit by damaging ransomware attack

DaVita confirmed suffering an attack that crippled its operations, says investigation is ongoing.

Barchart

Are Wall Street Analysts Predicting DaVita Stock Will Climb or Sink?

While DaVita has outperformed relative to the broader market over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

DaVita Earnings Preview: What to Expect

DaVita is set to announce its fourth-quarter results next month, with analysts forecasting a double-digit growth in the company’s bottom-line figure.

Barchart

DaVita Stock: Is DVA Outperforming the Healthcare Sector?

Despite DaVita’s recent outperformance relative to its broader sector, Wall Street analysts remain cautious about the stock’s prospects.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.